Supramolecular PEGylation of biopharmaceuticals
The covalent modification of therapeutic biomolecules has been broadly explored, leading to a number of clinically approved modified protein drugs. These modifications are typically intended to address challenges arising in biopharmaceutical practice by promoting improved stability and shelf life of...
| Egile Nagusiak: | , , , , , , , , |
|---|---|
| Beste egile batzuk: | |
| Formatua: | Artikulua |
| Hizkuntza: | en_US |
| Argitaratua: |
National Academy of Sciences (U.S.)
2017
|
| Sarrera elektronikoa: | http://hdl.handle.net/1721.1/111202 https://orcid.org/0000-0003-0624-3532 https://orcid.org/0000-0002-2301-7126 https://orcid.org/0000-0002-8227-953X https://orcid.org/0000-0003-4255-0492 https://orcid.org/0000-0001-5629-4798 |
| Gaia: | The covalent modification of therapeutic biomolecules has been broadly explored, leading to a number of clinically approved modified protein drugs. These modifications are typically intended to address challenges arising in biopharmaceutical practice by promoting improved stability and shelf life of therapeutic proteins in formulation, or modifying pharmacokinetics in the body. Toward these objectives, covalent modification with poly(ethylene glycol) (PEG) has been a common direction. Here, a platform approach to biopharmaceutical modification is described that relies on noncovalent, supramolecular host–guest interactions to endow proteins with prosthetic functionality. Specifically, a series of cucurbit[7]uril (CB[7])–PEG conjugates are shown to substantially increase the stability of three distinct protein drugs in formulation. Leveraging the known and high-affinity interaction between CB[7] and an N-terminal aromatic residue on one specific protein drug, insulin, further results in altering of its pharmacological properties in vivo by extending activity in a manner dependent on molecular weight of the attached PEG chain. Supramolecular modification of therapeutic proteins affords a noncovalent route to modify its properties, improving protein stability and activity as a formulation excipient. Furthermore, this offers a modular approach to append functionality to biopharmaceuticals by noncovalent modification with other molecules or polymers, for applications in formulation or therapy. |
|---|